Unknown

Dataset Information

Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas.


ABSTRACT:

Background

Recurrent high-grade gliomas in adults remain a deadly cancer with median survival of less than 1 year. In the absence of effective agents, immunotherapy with checkpoint inhibitors has been adopted as a potentially beneficial next step for recurrences with hypermutated or mismatch repair-mutated phenotypes. The rationale for their use, however, is based on case reports and studies with other types of cancer.

Methods

We reviewed 4 cases of hypermutated or mismatch repair-mutated recurrent high-grade gliomas treated with checkpoint inhibitors.

Results

All cases had recurrent high-grade glioma that harbored either a hypermutated phenotype and/or a mismatch repair mutation. Treatment with checkpoint inhibitor therapy resulted in no significant response.

Conc

SUBMITTER: Ahmad H 

PROVIDER: S-EPMC6899050 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature